Irene C. Waizenegger

Zongertinib in HER2-altered breast cancer: Preclinical activity and preliminary results from a phase Ia dose-escalation study.

David Berz, Frans L. Opdam, Daniela Maier, Kerstin Moeldner et autres

1023 Background: Preclinical studies have demonstrated that zongertinib, an irreversible TKI, selectively and potently inhibits oncogenic HER2 in a variety of cancer models. An ongoing Phase (Ph) Ia/Ib dose escalation/expansion trial (NCT04886804) has demonstrated preliminary clinical activity of zongertinib across a range …

us, nl, de, at, jp (code pays fourni par la source)

Supplementary Data Table 2 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

PRISM screen raw data.

Data from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

Abstract Mutations in ERBB2 (encoding HER2) occur in 2% to 4% of non–small cell lung cancer (NSCLC) and confer poor prognosis. ERBB-targeting tyrosine kinase inhibitors, approved for treating other HER2-dependent cancers, are ineffective in HER2-mutant NSCLC due to dose-limiting toxicities or suboptimal …

Supplementary Figure 5 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

High-throughput zongertinib PRISM drug sensitivity screen and biomarker analysis.

Supplementary Figure 4 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

High-throughput PRISM drug sensitivity screen in cancer cell lines.

Supplementary Data Table 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

Tempus data analysis results.

Supplementary Figure 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

In vitro biomarker modulation of (phospho-)protein and mRNA levels post poziotinib or zongertinib treatment.

Supplementary Figure 2 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

Graphical NMR spectra of zongertinib and BI-3999

Supplementary Data Table 1 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

MANO method and results. Sheet 1: Primer sequence for the bar code amplification. Sheet 2: Primer sequence for next-generation sequencing analysis. Sheet 3: Raw data for zongertinib (BI 1810631 in table) drug sensitivity assay.

Supplementary Figure 7 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

In vivo tumor responses for zongertinib monotherapy or combinations.

Supplementary Figure 6 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

Tolerability data for zongertinib in mouse xenotransplantation assays.

Supplementary Figure 1 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

Synthesis and in vivo DMPK profile of zongertinib